Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection

Clinical Infectious Diseases

Volumn 35, Issue 7, 2002, Pages 873-879

  Cooper, Curtis L ^a   Cameron, D William ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COMORBIDITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; RNA, VIRAL;

EID: 0036787488     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342388     Document Type: Review

References (71)

1. Allory Y, Charlotte F, Benhamou Y, et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. MULTIVIRC group. Hum Pathol 2000; 31:69-74.
2. Bierhoff E, Fisher HP, Willsch E, et al. Liver histology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997; 430:271-7.
3. Guido M, Rugge M, Fattovich G, et al. Human immunodeficiency virus infection and hepatitis C pathology. Liver 1994; 14:314-9.
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. Hepatology 1999; 30:1054-8.
5. Dragoni F, Cafolla A, Gentile G, et al. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica 1999; 84:525-9.
6. Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179:1254-8.
7. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
8. Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
9. Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
10. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
11. Program and abstracts of the 13th World AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, 2000.
12. Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Paris: European AIDS Clinical Society, 2001.
13. Program and abstracts of the 38th Interscience Conference on Antimicrobials and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
14. Program and abstracts of the 39th Interscience Conference on Antimicrobials and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
15. Program and abstracts of the 40th Interscience Conference on Antimicrobials and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
16. Program and abstracts of the 41st Interscience Conference on Antimicrobials and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
17. Halfon P, Bourliere M, Halimi G, et al. Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitative methods: branched DNA and Amplicor Monitor. J Clin Microbiol 1998; 36:2073-5.
18. Hollingsworth RC, Sillekens P, van Deursen P, Neal KR, Irving WL. Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. Trent HCV Study Group. J Hepatol 1996; 25:301-6.
19. Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor hepatitis C virus monitor test, version 2.0. Am J Clin Pathol 2000; 114:180-7.
20. Lunel F, Cresta P, Vitour D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology 1999; 29:528-35.
21. COBAS Amplicor HCV Monitor Test, version 2.0. Product monogram. Nutley, NJ: Roche Diagnostics, 1998.
22. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 or 2, Roche Monitor Assays, and in-house limiting dilution methods. J Clin Microbiol 1997; 35: 187-92.
23. Martinot-Peignoux M, Boyer N, Breton VL, et al. A new step toward the standardization of serum hepatitis C virus RNA quantification in patients with chronic hepatitis C. Hepatology 2000; 31:726-9.
24. Schmid P, Tong M, Conrad A, McHutchison J, Blatt LM. Analysis of the variability of freezer stored serum samples from hepatitis C virus RNA analysis by the SUPERQUANT method: results of a 16-year retrospective study. J Virol Methods 1999; 82:201-6.
25. Madejon A, Manzano ML, Arocena C, Castillo I, Carreno V. Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands. J Hepatol 2000; 32:1019-25.
26. Halfon P, Khiri H, Gerolami V, et al. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol 1996; 25:307-11.
27. Yeo AE, Ghany M, Conry-Cantilena C, et al. Stability of HVC-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8:256-63.
28. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998; 28:1702-6.
29. Eyster ME, Fried MW, DiDisceglie AM, et al. Increasing hepatitis C virus RNA levels in haemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84:1020-3.
30. Beld M, Penning M, Lukashow V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998; 244:504-12.
31. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. Hemophilia Growth and Development Study. J Acquir Immune Defic Syndr 2001; 26:466-72.
32. Yokozaki S, Takamatsu J, Nakano I, et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96:4293-9.
33. Cribier B, Schmitt C, Rey D, et al. HIV increases hepatitis C viraemia irrespective of hepatitis C viral genotype. Res Virol 1997; 148:267-81.
34. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6:203-8.
35. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088-96.
36. Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 1999; 31:593-7.
37. Adinolfi LE, Utili R, Andreana A, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001; 46:1677-83.
38. Nousbaum J-B, Pol S, Bnalpas B, Landais P, Berthelot P, Brechot C, and the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122:161-8.
39. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180:2027-9.
40. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M. Effect of alcoholic consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-22.
41. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20:1115-20.
42. - patients [abstract 278]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
43. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-41.
44. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-5.
45. Puoti M, Gargiulo F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000; 181:2033-6.
46. Matsiota-Bernard P, Vrioni G, Onody C, Bernard L, de Truchis P, Peronne C. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. Int J Antimicrob Agents 2001; 17:155-7.
47. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral therapy. AIDS 1998; 12:116-7.
48. Zylberberg H, Chaix M-L, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26:1104-45.
49. Rockstroh JK, Theisen A, Kaiser R, et al. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS 1998; 12:829-30.
50. Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000; 14:212.
51. Garcia-Samaniego J, Bravo R, Castilla J, et al. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998; 28:526-7.
52. John M, Flexman J, French M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289-93.
53. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27:1255-8.
54. Rodriguez-Rosado R, Garcia-Samaniego R, Soriano V, et al. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12:1256.
55. Gavazzi G, Bouchard O, Leclerq P, et al. Increase in transaminases in HCV- and HIV-coinfected patients with undetectable HIV viral load after HAART: is there a role for CD8 T cells? [abstract 102]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society of Microbiology, 1999.
56. Cribier B, Schmitt C, Rey D, et al. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res Virol 1996; 147:263-6.
57. Kovacs JA, Bechtel C, Davey RT, et al. Combination therapy with didanosine and interferon-α in human immunodeficiency virus-infected patients: results of a phase I/II trial. J Infect Dis 1996; 173:840-8.
58. 6/L: results of the Zidon trial. Zidon Study Group. AIDS 1995; 9:1025-35.
59. Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for HIV infection. J Infect Dis 1999; 180:574-5.
60. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334:1011-8.
61. Hirsh M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type I infection and prior antiretroviral therapy. J Infect Dis 1999; 180:659-65.
62. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med 1999; 341:1865-73.
63. Bush C, Nagabhairu N, Markowitz E, et al. Changes in HCV viral load in HIV patients during HAART therapy and after therapy [abstract 192]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
64. Gavazzi G, Bouchard O, LeClercq P, et al. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? AIDS Res Hum Retrovirus 2000; 16:1021-3.
65. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001; 33:1579-85.
66. Kupfer B, Kochan B, Quirishi N, Rockstroh JK. Does HAART help to control HC viraemia in HIV coinfected haemophiliacs? [abstract 9]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Paris: European AIDS Clinical Society, 2001.
67. Poynard T, McHutchison J, Goodman Z, Ling M, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31:211-8.
68. McHutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
69. Canadian Consensus Conference on the Management of Viral Hepatitis. Can J Gasteroenterol 2000; 14(Suppl B):5B-20B.
70. Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis c virus. Lancet 1998; 352:1426-32.
71. Benhamou Y, di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.